CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 88 enrolled
Drug / intervention
Cyclophosphamide +12 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01424982
NCT01424982Phase 2Active
CompareCT.gov

Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

M.D. Anderson Cancer Center·interventional·Posted Aug 29, 2011·Updated Apr 15, 2026

In Brief

A Phase 2 clinical trial evaluating Cyclophosphamide, Cytarabine, and 11 other interventions for Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 6 related conditions. Active but no longer recruiting, targeting 88 participants across 1 site.

Detailed Summary

This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy and ponatinib hydrochloride may be an effective treatment for acute lymphoblastic leukemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Untreated Adult Acute Lymphoblastic Leukemia
CountriesUnited States
Collaborators--

Timeline

Phase 2Active
20122013201420152016201720182019202020212022202320242025202620272028
First PostedAug 29, 2011
Enrollment StartOct 5, 2011
Primary CompletionOct 31, 2027
TodayJul 1, 2026
Enrollment to primary: 16.1 yearsPosted 14.8 years agoPrimary completion in 1.3 years

Interventions

Cyclophosphamidedrug

Given IV

Cytarabinedrug

Given IV

Dexamethasonedrug

Given IV or PO

Doxorubicindrug

Given IV

Doxorubicin Hydrochloridedrug

Given IV

Laboratory Biomarker Analysisother

Correlative studies

Methotrexatedrug

Given IV

Ponatinibdrug

Given PO

Ponatinib Hydrochloridedrug

Given PO

Prednisonedrug

Given PO

Rituximabbiological

Given IV

Vincristinedrug

Given IV

Vincristine Sulfatedrug

Given IV